About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Monthly Archives: November 2009
Risk Communication Advisory Committee – That Other FDA Meeting This Week – Don’t Ignore It!
So many people have been laser focused on the FDA's Part 15 Meeting on the use of social media to promote medical products being held this week in Washington, that the meeting on the same two-days of the Risk Communications … Continue reading
Posted in Uncategorized
Comments Off on Risk Communication Advisory Committee – That Other FDA Meeting This Week – Don’t Ignore It!
AstraZeneca Joins the List of Corporate Bloggers
As blogging evolved, more and more corporations have begun corporate blogs as a means of engaging the public in dialog. Pharmaceutical companies, representing a highly regulated industry, has been much more reticent and cautious in participating in this medium. Meanwhile, … Continue reading
Posted in New and Social Media
1 Comment
Covering FDA’s Part 15 Meeting on Social Media and Medical Product Promotion
Anyone in the pharma biz, and particularly the communications biz, is aware that on November 12 and 13, the FDA is holding a Part 15 meeting to gather input regarding the regulation of promotional communications through social media. The meeting … Continue reading
Posted in Uncategorized
2 Comments
P&G Gets Warning Letter, FDA Takes it Back, P&G Gets Warning Letter
Last week, the FDA sent a warning letter to Procter & Gamble, presumably the same one that was posted a few weeks before by the agency, and then retracted. Well, it is either back, or we are all experiencing a … Continue reading
Posted in Uncategorized
Comments Off on P&G Gets Warning Letter, FDA Takes it Back, P&G Gets Warning Letter